Search Results

There are 845507 results for: content related to: FDA bridging analyses confirmed in clinical trial

  1. You have full text access to this OnlineOpen article
    Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

    British Journal of Clinical Pharmacology

    Volume 78, Issue 5, November 2014, Pages: 1043–1049, Mark Johnson, Julie Borland, Shuguang Chen, Paul Savina, Brian Wynne and Stephen Piscitelli

    Version of Record online : 20 OCT 2014, DOI: 10.1111/bcp.12428

  2. Boceprevir in liver transplant recipients

    Liver International

    Volume 35, Issue 1, January 2015, Pages: 192–197, Sammy Saab, Vignan Manne, Sherona Bau, Justin A. Reynolds, Ruby Allen, Leonard Goldstein, Francisco Durazo, Mohammed El-Kabany, Steven Han and Ronald W. Busuttil

    Version of Record online : 10 APR 2014, DOI: 10.1111/liv.12548

  3. You have free access to this content
    Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers

    Hepatology

    Volume 56, Issue 5, November 2012, Pages: 1622–1630, Ellen Hulskotte, Samir Gupta, Fengjuan Xuan, Marga van Zutven, Edward O'Mara, Hwa-Ping Feng, John Wagner and Joan Butterton

    Version of Record online : 14 OCT 2012, DOI: 10.1002/hep.25831

  4. Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans

    Journal of Viral Hepatitis

    Volume 22, Issue 5, May 2015, Pages: 489–495, R. Gidwani, P. G. Barnett, J. D. Goldhaber-Fiebert, S. M. Asch, J. Lo, S. K. Dally and D. K. Owens

    Version of Record online : 24 NOV 2014, DOI: 10.1111/jvh.12344

  5. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations

    The Journal of Clinical Pharmacology

    Volume 55, Issue 5, May 2015, Pages: 517–524, Sandra Bodeau, Eric Nguyen-Khac, Caroline Solas, Youssef Bennis, Dominique Capron, Gilles Duverlie and Etienne Brochot

    Version of Record online : 4 FEB 2015, DOI: 10.1002/jcph.454

  6. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

    Journal of Viral Hepatitis

    Volume 19, Issue s2, May 2012, Pages: 1–26, I. M. Jacobson, J.-M. Pawlotsky, N. H. Afdhal, G. M. Dusheiko, X. Forns, D. M. Jensen, F. Poordad and J. Schulz

    Version of Record online : 8 MAR 2012, DOI: 10.1111/j.1365-2893.2012.01590.x

  7. You have free access to this content
    AASLD Abstracts

    Hepatology

    Volume 56, Issue S1, October 2012, Pages: 191A–1144A,

    Version of Record online : 1 OCT 2012, DOI: 10.1002/hep.26040

  8. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b

    Journal of Viral Hepatitis

    Volume 19, Issue 2, February 2012, Pages: 120–127, J. Vermehren, S. Susser, C. M. Lange, N. Forestier, U. Karey, E. Hughes, R. Ralston, X. Tong, S. Zeuzem and C. Sarrazin

    Version of Record online : 1 MAR 2011, DOI: 10.1111/j.1365-2893.2011.01449.x

  9. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings

    Journal of Viral Hepatitis

    Volume 22, Issue 9, September 2015, Pages: 691–700, A. A. Butt, P. Yan, O. S. Shaikh, M. S. Freiberg, V. Lo Re III, A. C. Justice, K. E. Sherman and for the ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team

    Version of Record online : 18 DEC 2014, DOI: 10.1111/jvh.12375

  10. You have free access to this content
    Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis

    Alimentary Pharmacology & Therapeutics

    Volume 39, Issue 10, May 2014, Pages: 1213–1224, V. Saxena, M. M. Manos, H. S. Yee, L. Catalli, E. Wayne, R. C. Murphy, V. A. Shvachko, M. P. Pauly, J. Chua, A. Monto and N. A. Terrault

    Version of Record online : 23 MAR 2014, DOI: 10.1111/apt.12718

  11. Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 32, Issue 2, February 2012, Pages: 173–190, Olga M. Klibanov, Stephen B. Vickery, Jacqueline L. Olin, Lisa S. Smith and Shannon H. Williams

    Version of Record online : 30 JAN 2012, DOI: 10.1002/PHAR.1046

  12. You have free access to this content
    Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment

    Hepatology

    Volume 55, Issue 4, April 2012, Pages: 1048–1057, Patrick R. Harrington, Wen Zeng and Lisa K. Naeger

    Version of Record online : 1 MAR 2012, DOI: 10.1002/hep.24791

  13. You have free access to this content
    Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects

    Journal of Gastroenterology and Hepatology

    Volume 29, Issue 8, August 2014, Pages: 1574–1581, Eric J Lawitz and Fernando E Membreno

    Version of Record online : 29 JUL 2014, DOI: 10.1111/jgh.12632

  14. You have full text access to this OnlineOpen article
    A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy

    CPT: Pharmacometrics & Systems Pharmacology

    Volume 4, Issue 1, January 2015, Pages: 37–40, C Laouénan, J Guedj, G Peytavin, TH Tram Nguyen, M Lapalus, F Khelifa-Mouri, N Boyer, F Zoulim, L Serfaty, J-P Bronowicki, M Martinot-Peignoux, O Lada, T Asselah, C Dorival, C Hézode, F Carrat, F Nicot, P Marcellin, F Mentré and for the ANRS CO20-CUPIC Study Group

    Version of Record online : 30 DEC 2014, DOI: 10.1002/psp4.8

  15. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis

    Liver International

    Volume 35, Issue 1, January 2015, Pages: 90–100, Jose L. Calleja, Juan M. Pascasio, Belén Ruiz-Antorán, Francisco Gea, Rafael Bárcena, Juan R. Larrubia, Ramón Pérez-Álvarez, Jose M. Sousa, Manuel Romero-Gómez, Ricard Solá, Juan de la Revilla, Javier Crespo, Jose M. Navarro, Juan I. Arenas, Manuel Delgado, Conrado M. Fernández-Rodríguez, Ramon Planas, Maria Buti, Xavier Forns and the Spanish Group for the Study of the Use of Direct-Acting Drugs Hepatitis C with Severe Fibrosis

    Version of Record online : 15 SEP 2014, DOI: 10.1111/liv.12656

  16. You have free access to this content
    HCV Therapeutics: Approved Agents

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 1091A–1168A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26880

  17. You have free access to this content
    Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir

    Alimentary Pharmacology & Therapeutics

    Volume 41, Issue 7, April 2015, Pages: 671–685, R. K. Sterling, A. Kuo, V. K. Rustgi, M. S. Sulkowski, T. G. Stewart, J. M. Fenkel, H. El-Genaidi, M. A. Mah'moud, G. M. Abraham, P. W. Stewart, L. Akushevich, D. R. Nelson, M. W. Fried and A. M. Di Bisceglie

    Version of Record online : 28 JAN 2015, DOI: 10.1111/apt.13095

  18. Boceprevir

    Standard Article

    Handbook of Metabolic Pathways of Xenobiotics

    Zhi-Yi Zhang

    Published Online : 1 OCT 2014, DOI: 10.1002/9781118541203.xen123

  19. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

    Journal of Viral Hepatitis

    Volume 22, Issue 5, May 2015, Pages: 469–480, S. Bruno, S. Bollani, A. L. Zignego, J. M. Pascasio, C. Magni, A. Ciancio, M. Caremani, A. Mangia, S. Marenco, S. Piovesan, L. Chemello, S. Babudieri, A. Moretti, F. Gea, C. Colletta, R. Perez-Alvarez, X. Forns, J. R. Larrubia, J. Arenas, J. Crespo, V. Calvaruso, F. Ceccherini Silberstein, P. Maisonneuve, A. Craxì, J. L. Calleja and Italian and Spanish (IAS)-BoC Study Group

    Version of Record online : 14 OCT 2014, DOI: 10.1111/jvh.12342

  20. You have free access to this content
    Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort

    Alimentary Pharmacology & Therapeutics

    Volume 39, Issue 1, January 2014, Pages: 93–103, L. I. Backus, P. S. Belperio, T. A. Shahoumian, R. Cheung and L. A. Mole

    Version of Record online : 10 NOV 2013, DOI: 10.1111/apt.12546